This medicine, could help prevent heart disease associated with obesity

 
Related

Be careful! Salmonella outbreak linked to papayas spreads

Health at home
308 points

FDA proposes reducing nicotine in cigarettes

Health at home
212 points



Most recent

bawaseer Ka Ilaj In Urdu | Piles Hemorrhoid Treatment In Urdu

HI Raja
24 points

He is Comando, the dog that faithfully awaits the arrival of the Argentine submarine ARA San Juan

About pets
38 points

These parents put their baby in a microwave on!

You have to know
186 points

"My biggest dream": a letter from a child to his abusive parents

Amazing histories
38 points

Video: A homophobic senator is found in a hotel with a minor

You have to know
48 points
SHARE
TWEET
(futurity.org) In a study conducted by the University of Missouri School of Medicine, a pre-written diabetes medicine, known as linagliptin, could help prevent heart disease associated with obesity and intake of a high-fat diet.

This medicine, could help prevent heart disease associated with obesity

The finding may have implications for management of cardiovascular diseases in humans, particularly for obese and diabetic premenopausal women, who are more at risk of developing heart disease―even more than men of similar age and with similar health issues.

“In previous studies, we showed that young, female mice consuming a Western diet, high in fat, sucrose, and high fructose corn syrup, not only gained weight, but also exhibited vascular stiffening consistent with obese premenopausal women,” says Vincent DeMarco, a research associate professor of endocrinology at the University of Missouri School of Medicine and the lead author of the study.

“Our current study sought to understand if linagliptin prevents cardiac stiffening caused by eating a Western-style diet.”

Linagliptin is a medication prescribed to lower blood glucose in patients with type 2 diabetes. The medication works by blocking the enzyme dipeptidyl peptidase-4, or DPP-4. Previous studies have shown that DPP-4 inhibitors offer protection against vascular inflammation and oxidative stress―conditions associated with cardiovascular stiffening.

DeMarco’s team studied 34 female mice that were fed either a normal diet or a simulated Western diet for four months. Another group of mice were fed a Western diet containing a low dose of linagliptin. The team used an ultrasound system, similar to that used in humans, to evaluate the function of the left ventricle of the heart.

“A heartbeat actually is a two-part pumping action that takes less than a second in healthy humans,” DeMarco says. “The first part, known as diastole, involves relaxation of the left ventricle while it fills with oxygenated blood from the lungs. After the left ventricle fills with blood, it then contracts and pushes blood into the aorta. This part of the cardiac cycle is referred to as systole.

“If the left ventricle becomes stiffer it will not be able to relax normally, and diastole will be impaired. This form of heart disease is known as diastolic dysfunction, which is a risk factor for a more serious heart condition known as diastolic heart failure,” he explains.

The mice fed the Western diet alone gained weight, exhibited increased heart weight, and developed diastolic dysfunction. However, the mice fed the Western diet along with linagliptin did not develop diastolic dysfunction. They also exhibited less oxidative stress and inflammation in their hearts compared to the mice fed the Western diet alone.

“Oxidative stress and inflammation are two factors that can promote excess accumulation of collagen, also known as fibrosis, in the walls of the left ventricle,” DeMarco says. “In our study, we found that Western diet-fed mice had increased fibrosis in the left ventricle that was prevented by linagliptin.”

The team also found that linagliptin suppressed not only DPP-4 activity, but also TRAF3IP2 production. TRAF3IP2 is a protein responsible for initiating tissue oxidative stress, inflammation, and fibrosis in the heart.

“This was a major novel finding of our study,” DeMarco says. “However, further research is required to determine exactly how linagliptin affects the function of this important protein.”

DeMarco also cautions that linagliptin, like other DPP-4 inhibitors, can be expensive without insurance coverage.

“Based on the results of this research and our previous studies, it is tempting to speculate that linagliptin could reduce the risk of cardiovascular complications associated with obesity and type 2 diabetes,” DeMarco says. “However, ongoing clinical trials will help determine what, if any, cardio-protective role linagliptin could play in the management of obesity-related heart disease.”

The study appears in Cardiovascular Diabetology. Boehringer Ingelheim Pharmaceuticals Inc., the National Institutes of Health, and the Department of Veterans Affairs provided funding for the study.

Fuente: www.futurity.org
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content